Cargando…
Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients
PURPOSE: COVID-19 in lung transplant recipients (LTR) results in case-fatality rate of 10-46%. Disease severity is variable and it is unclear why certain groups of patients develop severe disease. Recent report suggests that 10% of patients with life threatening COVID-19 have auto-antibodies (AAbs)...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988551/ http://dx.doi.org/10.1016/j.healun.2022.01.313 |
_version_ | 1784682985925115904 |
---|---|
author | Kaza, V. Mahan, L. Banga, A. Mohanka, M. Bollineni, S. Lawrence, A. Joerns, J. Torres, F. Timofte, I. Lacelle, C. La Hoz, R. Galli, J. Kozlitina, J. Zhu, C. Li, Q. |
author_facet | Kaza, V. Mahan, L. Banga, A. Mohanka, M. Bollineni, S. Lawrence, A. Joerns, J. Torres, F. Timofte, I. Lacelle, C. La Hoz, R. Galli, J. Kozlitina, J. Zhu, C. Li, Q. |
author_sort | Kaza, V. |
collection | PubMed |
description | PURPOSE: COVID-19 in lung transplant recipients (LTR) results in case-fatality rate of 10-46%. Disease severity is variable and it is unclear why certain groups of patients develop severe disease. Recent report suggests that 10% of patients with life threatening COVID-19 have auto-antibodies (AAbs) against type 1 interferons (IFN-1) but very few describe their impact in LTR. We therefore sought to identify AAbs in LTR with COVID-19 by using a customized proteomic microarray (CPM) bearing 120 antigens. METHODS: We retrieved samples collected for routine care within 3 months prior to and after diagnosis of COVID-19 of 13 LTR. IgA and IgG AAbs were analyzed using CPM. Predefined antibody score (ab-score) was used for downstream analysis. COVID severity was defined as per center for disease control guidelines. Changes in ab-scores from pre- to post-COVID were assessed via Wilcoxon signed-rank tests; association between continuous variables and AAbs using Spearman's correlation. Linear mixed-effects models were used to analyze the association between changes in AAbs pre- to post-COVID and COVID severity. RESULTS: Among 13 LTR COVID severity was moderate (n=6), severe (n=4) and critical (n=3). Levels of 76 IgA antibodies and 9 IgG antibodies increased between pre and post covid samples (FDR adjusted p<0.05). In exploratory analysis, antibody response over time for one IgA antibody (IgA Nucleosome) and four IgG AAbs correlated with higher COVID severity (unadjusted p<0.05). IFN lambda is an antiviral cytokine and AAbs to it correlated with COVID severity (p=0.031). Such AAbs are shown to block the ability to block SARS-CoV-2 in vitro. No significant differences were observed in antibody response in the groups who were alive (n=9) versus deceased (n=4) and three inflammatory markers, ferritin, D dimer and absolute lymphocyte count. CONCLUSION: Change in antibody response of five AAbs correlated with COVID severity in a small group of LTR. The results of this study are considered exploratory and need further validation. |
format | Online Article Text |
id | pubmed-8988551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89885512022-04-11 Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients Kaza, V. Mahan, L. Banga, A. Mohanka, M. Bollineni, S. Lawrence, A. Joerns, J. Torres, F. Timofte, I. Lacelle, C. La Hoz, R. Galli, J. Kozlitina, J. Zhu, C. Li, Q. J Heart Lung Transplant (292) PURPOSE: COVID-19 in lung transplant recipients (LTR) results in case-fatality rate of 10-46%. Disease severity is variable and it is unclear why certain groups of patients develop severe disease. Recent report suggests that 10% of patients with life threatening COVID-19 have auto-antibodies (AAbs) against type 1 interferons (IFN-1) but very few describe their impact in LTR. We therefore sought to identify AAbs in LTR with COVID-19 by using a customized proteomic microarray (CPM) bearing 120 antigens. METHODS: We retrieved samples collected for routine care within 3 months prior to and after diagnosis of COVID-19 of 13 LTR. IgA and IgG AAbs were analyzed using CPM. Predefined antibody score (ab-score) was used for downstream analysis. COVID severity was defined as per center for disease control guidelines. Changes in ab-scores from pre- to post-COVID were assessed via Wilcoxon signed-rank tests; association between continuous variables and AAbs using Spearman's correlation. Linear mixed-effects models were used to analyze the association between changes in AAbs pre- to post-COVID and COVID severity. RESULTS: Among 13 LTR COVID severity was moderate (n=6), severe (n=4) and critical (n=3). Levels of 76 IgA antibodies and 9 IgG antibodies increased between pre and post covid samples (FDR adjusted p<0.05). In exploratory analysis, antibody response over time for one IgA antibody (IgA Nucleosome) and four IgG AAbs correlated with higher COVID severity (unadjusted p<0.05). IFN lambda is an antiviral cytokine and AAbs to it correlated with COVID severity (p=0.031). Such AAbs are shown to block the ability to block SARS-CoV-2 in vitro. No significant differences were observed in antibody response in the groups who were alive (n=9) versus deceased (n=4) and three inflammatory markers, ferritin, D dimer and absolute lymphocyte count. CONCLUSION: Change in antibody response of five AAbs correlated with COVID severity in a small group of LTR. The results of this study are considered exploratory and need further validation. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988551/ http://dx.doi.org/10.1016/j.healun.2022.01.313 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (292) Kaza, V. Mahan, L. Banga, A. Mohanka, M. Bollineni, S. Lawrence, A. Joerns, J. Torres, F. Timofte, I. Lacelle, C. La Hoz, R. Galli, J. Kozlitina, J. Zhu, C. Li, Q. Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients |
title | Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients |
title_full | Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients |
title_fullStr | Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients |
title_full_unstemmed | Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients |
title_short | Autoantibodies and Severity of COVID-19 in Lung Transplant Recipients |
title_sort | autoantibodies and severity of covid-19 in lung transplant recipients |
topic | (292) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988551/ http://dx.doi.org/10.1016/j.healun.2022.01.313 |
work_keys_str_mv | AT kazav autoantibodiesandseverityofcovid19inlungtransplantrecipients AT mahanl autoantibodiesandseverityofcovid19inlungtransplantrecipients AT bangaa autoantibodiesandseverityofcovid19inlungtransplantrecipients AT mohankam autoantibodiesandseverityofcovid19inlungtransplantrecipients AT bollinenis autoantibodiesandseverityofcovid19inlungtransplantrecipients AT lawrencea autoantibodiesandseverityofcovid19inlungtransplantrecipients AT joernsj autoantibodiesandseverityofcovid19inlungtransplantrecipients AT torresf autoantibodiesandseverityofcovid19inlungtransplantrecipients AT timoftei autoantibodiesandseverityofcovid19inlungtransplantrecipients AT lacellec autoantibodiesandseverityofcovid19inlungtransplantrecipients AT lahozr autoantibodiesandseverityofcovid19inlungtransplantrecipients AT gallij autoantibodiesandseverityofcovid19inlungtransplantrecipients AT kozlitinaj autoantibodiesandseverityofcovid19inlungtransplantrecipients AT zhuc autoantibodiesandseverityofcovid19inlungtransplantrecipients AT liq autoantibodiesandseverityofcovid19inlungtransplantrecipients |